Dr Reddy’s Signs Pact with Coya Therapeutics for Investigational Therapy of ALS

Additionally, Dr Reddy’s will make a $7.5 million upfront payment to Coya for the purpose. This arrangement is in addition to the in-licensing agreement with Dr Reddy signed in early 2023.

Global Pharmaceutical player, Dr Reddy's Laboratories SA subsidiary has inked a licence agreement with Coya Therapeutics for the development and commercialisation of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).

As per the terms, Coya has granted Dr Reddy’s an exclusive licence to commercialise COYA 302, a proprietary co-pack kit containing a combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the United States, Canada, the European Union and the United Kingdom for ALS.

Further, Dr Reddy’s will make a $7.5 million upfront payment to Coya for the purpose. This arrangement is in addition to the in-licencing agreement with Dr Reddy’s signed in early 2023.

Moreover, Coya retains the right to commercialise COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the US.

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. This disease is characterised by the gradual degeneration and death of motor neurons, which are responsible for controlling voluntary muscles. As these motor neurons die, the ability of the brain to initiate and control muscle movement is lost.

Sharing his thoughts, Marc Kikuchi, CEO, Dr Reddy Laboratories, North America, said, “With this promising biologic product, we hope to reach many more patients around the world in keeping with our aim of serving over 1.5 billion patients by 2030."

Furthermore, Coya is eligible to receive sales-based milestone payments of up to $677.25 million linked to tiers of cumulative net sales being achieved over several years.

In addition, Dr Reddy’s will pay Coya royalties based on a percentage net sales of COYA 302 ranging from low to middle teens.

Founded in 1984, Dr Reddy's is a global pharmaceutical company that offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) products.

In November this year, Dr Reddy’s launched the USFDA-approved wearable ‘Nerivio ’ for migraine management in India. Patients can use the device within 60 minutes of the onset of a headache for acute migraine treatment or every alternate day for migraine prevention. The app enables users to control the intensity levels of the device and includes an interactive migraine diary for symptom logging, response tracking, and insightful analytics.